{"id":"F2007B01080","name":"National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 7 of 2001)","slug":"national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":62614,"registerId":"commonwealth-F2007B01080-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 7 of 2001)","content":"COMMONWEALTH OF AUSTRALIA\n\nNational Health Act 1953\n\nPHARMACEUTICAL BENEFITS\n\nDECLARATION UNDER SUBSECTION 85 (2AA)\n\nNo. PB 7 of 2001\n\nI, BRETT ANTHONY LENNON, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Aged Care and Delegate of the Minister for Health and Aged Care, having in accordance with subsection 85 (2AB) of the National Health Act 1953 obtained the advice of the Pharmaceutical Benefits Advisory Committee, pursuant to subsection 85 (2AA) of the National Health Act 1953, hereby make the following Declaration:\n\n1.  This Declaration commences on 1 August 2001.\n\n2. The drugs and medicinal preparations specified in the Schedule to this Declaration shall cease to be drugs and medicinal preparations to which Part VII of the National Health Act 1953 applies.\n\nTHE SCHEDULE\n\nNadroparin Calcium\n\nDated this 5th day of July 2001.\n\nBRETT ANTHONY LENNON\n\nAssistant Secretary\n\nPharmaceutical Benefits Branch\n\nDepartment of Health and Aged Care\n\nDelegate of the Minister for Health and Aged Care","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":2002},"content_quality":"ok","complexity_score":1,"scope_assessment":{"changed":false,"description":"This declaration performs the precise function authorised by section 85(2AA) of the National Health Act: specifically delisting an individual pharmaceutical product from the PBS following expert committee advice. The scope remains strictly limited to the administrative removal of Nadroparin Calcium with no expansion beyond the statutory purpose."},"complexity_factors":["Single, unambiguous administrative action affecting only one named drug","No defined terms, exceptions, or conditional logic","Document length is approximately half a page","Minimal cross-referencing limited to the empowering provision (section 85(2AA))"],"plain_english_summary":"This declaration removes Nadroparin Calcium from the Pharmaceutical Benefits Scheme, so from 1 August 2001 patients prescribed it lost PBS subsidy and had to pay the full private price. The Assistant Secretary of the Pharmaceutical Benefits Branch made the change under delegated authority from the Minister for Health, following advice from the Pharmaceutical Benefits Advisory Committee. Drugs are usually delisted when they’re no longer cost‑effective, raise safety concerns, or suppliers stop offering them at the subsidised price."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001","history":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001/history","analysis":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001/analysis","conflicts":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001/conflicts","importantCases":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001/important-cases","documents":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-7-of-2001/documents"}}